Alaunos Therapeutics Yönetim
Yönetim kriter kontrolleri 3/4
Alaunos Therapeutics CEO'su Dale Hogue, Jan2024 tarihinde atandı, in görev süresi bir yıldan az. şirketin hisselerinin 0.25% doğrudan sahiptir ve bu hisselerin değeri $ 8.16K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3 yıl ve 3.9 yıldır.
Anahtar bilgiler
Dale Hogue
İcra Kurulu Başkanı
US$11.1k
Toplam tazminat
CEO maaş yüzdesi | n/a |
CEO görev süresi | less than a year |
CEO sahipliği | 0.2% |
Yönetim ortalama görev süresi | 3yrs |
Yönetim Kurulu ortalama görev süresi | 3.9yrs |
Son yönetim güncellemeleri
Recent updates
Health Check: How Prudently Does Alaunos Therapeutics (NASDAQ:TCRT) Use Debt?
Nov 10Alaunos wins bullish view at Wells Fargo on promise of cell therapy technology
Oct 04Alaunos posts 51% tumor reduction for lung cancer therapy
Sep 21Alaunos sheds 52% ahead of data readout for T-cell therapy platform
Sep 15Alaunos Therapeutics: Keep An Eye On Upcoming TCR-T Solid Tumor Study Data
Aug 31Alaunos Therapeutics GAAP EPS of -$0.05 beats by $0.02
Aug 15Is Alaunos Therapeutics (NASDAQ:TCRT) Weighed On By Its Debt Load?
Jul 26Is Alaunos Therapeutics (NASDAQ:TCRT) Using Debt Sensibly?
Apr 06Is ZIOPHARM Oncology (NASDAQ:ZIOP) A Risky Investment?
Dec 20Ziopharm: Waiting On FYE 2021 For Further Clinical Data On TCR-T/CAR-T Therapies
Jun 19ZIOPHARM records sharpest gain in nearly four months
Jun 09Will ZIOPHARM Oncology (NASDAQ:ZIOP) Spend Its Cash Wisely?
May 11ZIOPHARM Oncology, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 07How Much Of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Do Institutions Own?
Mar 09We're Hopeful That ZIOPHARM Oncology (NASDAQ:ZIOP) Will Use Its Cash Wisely
Jan 15ZioPharm highlights upcoming catalysts, says current cash runway into mid-2022
Jan 14Ziopharm Oncology to test non-viral CAR-T in leukemia and lymphoma patients
Dec 21Activist holder wins Ziopharm Oncology board seats
Dec 17Ziopharm Oncology CFO to step down
Dec 14What Is The Ownership Structure Like For ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)?
Nov 23Ziopharm says WaterMill’s nominees lack experience, White Rock backs proposal on board reconstitution
Nov 20ZIOPHARM Oncology, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 06Ziopharm Oncology thumbs down on investor's call for board seats
Nov 02CEO
Dale Hogue (54 yo)
less than a year
Görev süresi
US$11,090
Tazminat
Mr. Dale Curtis Hogue, Jr. is Director of Alaunos Therapeutics, Inc. from December 29, 2023 and also serves as Interim Chief Executive Officer from January 20, 2024. Mr. Hogue has worked in various roles...
Liderlik Ekibi
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
Interim CEO & Director | less than a year | US$11.09k | 0.25% $ 8.2k | |
Senior VP of Legal | 3yrs | US$701.74k | 0% $ 0 | |
Vice President of Finance & Principal Accounting Officer | 3.2yrs | Veri yok | Veri yok |
3.0yrs
Ortalama Görev Süresi
47yo
Ortalama Yaş
Deneyimli Yönetim: TCRT 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3 yıldır).
Yönetim Kurulu Üyeleri
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
Interim CEO & Director | less than a year | US$11.09k | 0.25% $ 8.2k | |
Independent Chairman of the Board | 3.9yrs | US$900.26k | 0.076% $ 2.5k | |
Chairman of Scientific Advisory Board | 4.4yrs | Veri yok | Veri yok | |
Independent Director | 3.9yrs | US$103.26k | 0.97% $ 31.6k | |
Member of Scientific Advisory Board | 4.2yrs | Veri yok | Veri yok | |
Member of Scientific Advisory Board | 4.2yrs | Veri yok | Veri yok | |
Independent Director | 1.7yrs | US$84.01k | 0% $ 0 | |
Independent Director | 3.8yrs | US$104.26k | 0.52% $ 16.9k | |
Member of Scientific Advisory Board | no data | Veri yok | Veri yok |
3.9yrs
Ortalama Görev Süresi
58yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: TCRT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.9 yıldır).